Answers are grounded in this paper and cite their sources.
Objectives: Keloid recurrence remains common after intralesional triamcinolone acetonide (TAC), the first-line therapy, and microbial colonization of the deep dermis has been implicated in keloid pathobiology; however, TAC combined with an antimicrobial has not been tested in a controlled comparison.Methods: We conducted a two-center retrospective cohort study comparing intralesional TAC plus gentamicin with TAC alone in adults with keloid. The primary outcome was change in the Vancouver Scar Scale (VSS) from baseline to a standardized 12-month post-treatment assessment, scored independently by two blinded plastic surgeons (ICC 0.90) and analyzed by baseline-adjusted analysis of covariance; a paired survey cohort (n = 109) provided recurrence and symptom outcomes.Results: Among 48 patients (24 per group), VSS reduction was threefold greater with TAC plus gentamicin than with TAC alone (−3.00 vs −1.04; adjusted β = −2.00; 95% confidence interval [CI], −2.86 to −1.14; p < 0.001; Cohen d = 1.27), and 29% versus 0% achieved at least 50% reduction. The effect persisted after adjusting for session number and follow-up (E-value, 5.8). The survey cohort reported a higher recurrence-free proportion, longer time to recurrence, and faster symptom relief.Conclusions: Adding gentamicin to intralesional TAC was associated with greater scar improvement, but treatment was confounded with site of care; randomized confirmation is required before clinical adoption.
No takes yet. Share an insight, caveat, or question.
Park et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: